Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment currently leading the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, a unique and emerging class of DNA Damage Response (DDR) therapies.
By combining novel, proprietary drug candidates with advanced nanoparticle (NP) tumor delivery and an AI-native discovery platform, we aim to redefine the treatment of cancers resistant to traditional therapies with its lead drug candidate, ONC010: a nanoparticle-encapsulated PNKP inhibitor.
ONC010ᵀᴹ
The Next-Generation Drug Formulation
Proprietary Formula
Aims to prevent DNA repair to eliminate cancer cells
Enhanced Delivery
Nanoparticles ensure precision targeting
Optimized Results
Designed to work with chemo/radiation/surgery to potentially improve outcomes and reduce side effects
10 Year Growth Projection
Market Value in Billions $(USD)
Global cancer cases are projected to rise by 47% by 2040²
CAGR of 8.9%³
Existing treatment gaps in precision medicine and early diagnostics
Addressable market: Colorectal cancer alone represents a $18 billion market
Unmet needs include faster diagnostics and cost-effective therapies